OutSee, based in Cambridge, UK, is a pioneering genomics and drug discovery startup that leverages its proprietary AI platform, Nomaly, to predict disease risk and phenotype directly from a single genome—without relying on conventional genetic associations. Instead, Nomaly applies a hypothesis-free, biology-first model to uncover the underlying molecular drivers of disease, even from small or previously analyzed datasets. This approach enables deeper insights into complex conditions like CNS disorders, rare diseases, metabolic syndromes, and has already attracted £1.8 million in seed funding led by Ahren Innovation Capital to expand its in-house target discovery efforts and collaborate with pharma and biotech partners.